Patient monitoring
accelerate imrt vmat planning

How it works
rainbow SET™ technology

Masimo rainbow SET technology expands the capabilities of Philips lntelliVue patient monitors. Masimo rainbow SET is a non-invasive measurement platform that incorporates motion and low perfusionTM pulse oximetry.

Standard parameters

Masimo set pulse oximetry

Masimo SET™ pulse oximetry

pulse rate

Pulse rate

perfusion index

Perfusion Index

Optional parameters

Pleth variability index

Pleth Variability Index

Standard parameter

Total hemoglobin

Standard parameter

Methemoglobin saturation

Standard parameter


Standard parameter

Acoustic Respiration rate

Standard parameter

Oxygen content

Common measurement parameters


SpO2 - measure of oxygen saturation even through motion and low perfusion


SpHb1 - provides continuous visibility to changes – or lack of changes – in hemoglobin levels between invasive blood samples


PVi - measure of the dynamic changes in the Perfusion Index (PERF) that occur during one or more respiratory cycles

Intuitive display on Masimo measurements on Philips IntelliVue monitors

Clear and intuitive screen displays combine vital signs with Masimo rainbow SET parameters – providing trend data and current data on one easy-to-read screen.

Masimo rainbow SET parameters

Masimo rainbow SET parameters


SPO2 non-invasive oxygen saturation

SpHb non-invasive continuous haemoglobin

PVi Pleth Variability index

Pi PERF Perfusion index

SpOC non-invasive oxygen content

SpMet non-invasive methaemoglobin

SpCO Carboxyhemoglobin

RRa or RRac Acoustic respiration

Masimo rainbow Horizon trends

Horizon trends


Horizon trends clearly indicate timely changes in patient condition – to aid you to quickly identify meaningful clinical deviations and take appropriate actions.

Non-invasive rainbow SET technology

Advanced rainbow SET sensors utilise multiple wavelengths of light to measure total haemoglobin (SpHb), Pleth Variability Index (PVi), oxygen content (SpOC). carboxyhaemoglobin (SpCO) and methaemoglobin (SpMet) non-invasively and continuously.

SET Technology

Works with your IT, works for your clinical teams


Philips IntelliVue monitoring platform fits securely into your hospital’s IT environment to capture timely patient data and feed it to the EMR. Capitalise on your IT investments, support your care teams with clinically proven solutions – without the need to purchase additional equipment.


With more than 1 million monitors sold since 2002, the IntelliVue family of monitoring solutions offers a proven track record for quality.

Non-invasive measurement technology – in clinical practice

Peer reviews have found that using SpHb monitoring in conjunction with invasive blood sampling can deliver value in A&E, OR, and during transport.

Stat icon 1

In low blood loss surgical applications

Reduces unnecessary transfusions

>87% reduction in transfusion frequency

(from 4.5% to 0.6%)2


>90% reduction in average units transfused (from 0.1 to 0.01 units per patient)2

Stat icon 2

In high blood loss surgical applications

Reduces unnecessary transfusions

> 73% to 32% reduction in the percentage of patients receiving 3 or more units3*


> 47% reduction in average units transfused (1.9 to 1.0 per patient)3*

Initiate timely transfusions when transfusions are needed


Contact information

* This field is mandatory


By specifying your reason for contact we will be able to provide you with a better service.

We work with partners and distributors who may contact you about this Philips product on our behalf.


Final CEE consent

See more about Philips and Masimo

Philips IntelliVue with Rainbow SET

Philips IntelliVue with rainbow SET


Versatile platform provides continuous and non-invasive patient monitoring with leading haemoglobin measurement technology.

Philips and Masimo partnership

The partnership


Philips and Masimo have teamed up to create the future of measurements and monitoring.



Masimo clinical claims are referenced on this web page. All studies available at

(1) SpHb** monitoring is not intended to replace lab testing. Blood samples should be analyzed by lab instruments prior to clinical decision making.

(2) Transt . 2014. 5:237.DOl:10.4172/2155-9864.1000237

(3) Awada WN et al J Clin Mon it Comput. DOI 10.1007/s10877-015-9660-4.

*Study Protocol: In each group, if researchers noted SpHb trended downward below 10 g/dl, a red blood cell transfusion was started and continued until SpHb trended upward above 10 g/dl. The transfusion threshold of 10 g/dl was predetermined by the study protocol and may not be appropriate for all patients. Blood sampling was the same for the control and test group. Artertal blood was drawn from a 20 gauge radial.

You are about to visit a Philips global content page


You are about to visit a Philips global content page


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.